In vivo imaging of brain cancer using epidermal growth factor single domain antibody bioconjugated to near-infrared quantum dots

Download
  1. Get@NRC: In vivo imaging of brain cancer using epidermal growth factor single domain antibody bioconjugated to near-infrared quantum dots (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1166/jnn.2014.9076
AuthorSearch for: ; Search for: ; Search for:
TypeArticle
Journal titleJournal of Nanoscience and Nanotechnology
ISSN1533-4899
Volume14
Issue7
Pages53555362; # of pages: 8
SubjectEGFR protein, mouse; epidermal growth factor receptor; monoclonal antibody; quantum dot; animal; article; brain tumor; fluorescence microscopy; glioblastoma; human; infrared radiation; metabolism; methodology; molecular imaging; mouse; nude mouse; pathology; reproducibility; sensitivity and specificity; tumor cell line; Animals; Antibodies, Monoclonal; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Infrared Rays; Mice; Mice, Nude; Microscopy, Fluorescence; Molecular Imaging; Quantum Dots; Receptor, Epidermal Growth Factor; Reproducibility of Results; Sensitivity and Specificity
AbstractDiagnosis of glioblastoma multiform (GBM) with MRI lacks molecular information and requires a biopsy for pathologic confirmation. The EGFRvIII, is a constitutively active mutant of the EGF receptor, identified in a high percentage of brain cancers and associated with increased invasiveness and resistance, making it a good target to improve imaging and diagnosis. The present study shows that conjugation of near-infrared quantum dot (Qd800) to an anti-EGFRvIII single domain antibody, made of the variable region with an extra cysteine for site-specific conjugation (EG2-Cys), increased its internalization in U87MG-EGFRvIII cells in vitro compared to Qd800 conjugated with the Fc region of the antibody (EG2-hFc) or unconjugated. EG2-Cys also improved the contrast in Near-Infrared Imaging of mice bearing orthotopic glioblastoma. The increased accumulation was confirmed by fluorescence microscopy of brain sections. The specificity of EG2-Cys in brain tumor expressing the EGFRvIII mutant receptor may provide an accurate less invasive diagnosis and determine the level of tumor aggressiveness and resistance. Copyright © 2014 American Scientific Publishers All rights reserved.
Publication date
LanguageEnglish
AffiliationNational Research Council Canada (NRC-CNRC); NRC Institute for Biological Sciences (IBS-ISB)
Peer reviewedYes
NRC numberNRC-HHT-53273
NPARC number21272265
Export citationExport as RIS
Report a correctionReport a correction
Record identifiera5e45cec-5d76-4f0a-b0d3-a5823f1821ff
Record created2014-07-23
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)